Active — Not RecruitingPhase 2

Study of Re-Treatment With ALXN2220 in Patients With ATTR-CM

France, Germany, Netherlands35 participantsStarted 2025-08-28

Plain-language summary

This is a Phase 2, single-arm, multicenter study to evaluate the pharmacodynamics and safety of re-treatment with ALXN2220 in previous participants of Study NI006-101.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Must have received at least one dose of ALXN2220 in Study NI006-101 Exclusion Criteria: * Suspected or known intolerance/allergy to proteins or any components of the study drug * Treatment or study discontinuation in Study NI006-101 due to a treatment-related adverse event that was serious, severe or life-threatening (on Common terminology criteria for adverse events (CTCAE) scale) * Any new or uncontrolled condition after completion of Study NI006-101 that could make the participant unsuitable for participation in this study

What they're measuring

Change from Baseline to Week 48 in ECV measured by cMRI

Timeframe: Baseline, Week 48

Change from Baseline to Week 48 in Heart Retention/Whole Body Retention measured by scintigraphy

Timeframe: Baseline, Week 48

Trial details

NCT IDNCT07213583

SponsorNeurimmune AG

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2026-10-31

View on ClinicalTrials.gov More Amyloid Transthyretin Cardiomyopathy trials